GlassScriptPhysician profile
Joseph J Kessler
NPI 1104932458
$10,203.92
in general payments reported to CMS, 2019-2025
42 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $940 · 2021: $1,332 · 2022: $1,372 · 2023: $1,602 · 2024: $1,701 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,508 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,508.49 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,476.18 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,356.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,038.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,028.93 | 2019-2025 | |
| Pfizer INC. | $890.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $570.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $488.63 | 2020-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.01 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $300.65 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $211.49 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $202.68 | 2022-2025 | Rexulti, Nuedexta |
| Phathom Pharmaceuticals, INC. | $201.86 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $199.24 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $198.83 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $190.82 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.